Latest Healthcare News

Page 7 of 197
Third Age Health lifted first-half revenue 20.8% and statutory profit 38.4% as aged medical care services supplied almost all of the growth. The NZX-listed healthcare provider maintained its 4 cents per share quarterly dividend while warning that cybersecurity and technology investment could weigh on near-term earnings.
Ada Torres
Ada Torres
30 Oct 2026
Oakridge International reported a $267,000 operating cash outflow for the September quarter, leaving $343,000 in cash and an estimated 1.28 quarters of funding. The healthcare technology company expects collections and customer orders to improve cash flow, while evaluating additional funding and continuing to manage a potential historical claim from Teko International.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Hydralyte LLC recorded its first monthly operating profit in August, while a major cost reset cut its quarterly operating loss to US$66,900. But revenue fell 21.9%, cash narrowed to US$173,400 and the company is seeking up to A$1.4 million through a rights issue.
Victor Sage
Victor Sage
30 Oct 2026
Vitasora Health has signed a Florida healthcare agreement covering an initially addressable 9,000 Medicare patients while estimated October billable care minutes rose 50%. The ASX-listed company also agreed terms for an A$3 million secured facility, but the funding is not yet drawn and carries approval, interest and dilution conditions.
Ada Torres
Ada Torres
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.
Ada Torres
Ada Torres
30 Oct 2026
ImpediMed lifted quarterly revenue and recurring revenue, but weaker-than-expected BCRL sales and a near-total sales team rebuild have put its path to cash-flow break-even under pressure. The company ended September with $11.6 million in cash and 4.7 quarters of funding at the quarter’s operating burn.
Ada Torres
Ada Torres
30 Oct 2026
Cyclopharm has reported record third-quarter US Technegas revenue of A$1.62 million, with 76% generated by recurring consumable orders. Its installed base and hospital pipeline expanded sharply after new clinical guidelines preferred Technegas when available, while quarterly cash burn fell to A$0.9 million.
Ada Torres
Ada Torres
29 Oct 2026
Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive